HIV-1 virus isolates of a subtype and its differential diagnostics, a vaccine against HIV-1 virus infections of this subtype and method of producing same, use of the HIV-1 virus isolates

Three new HIV-1 isolates HIV-1 D747(ECACC V92082718), HIV-1 D757(ECACC V92082719) and HIV-1 D760(ECACC V92082720) are disclosed, which represent a further independent subtype of the HIV-1 family and have been recovered from Indian patients which at the time when the virus was isolated showed no typical AIDS symptoms. Also disclosed are vaccines against HIV-1 infections by this subtype and a process for producing the same, as well as the use of the HIV-1 infection, as well as for differential diagnosis.

The invention relates to new HIV-1 virus isolates of a subtype, vaccines
 against HIV-1 virus infections of this subtype, methods of producing same,
 and the use of the virus isolates for the production of vaccines and for
 differential diagnostics.
 Hitherto, efforts to develop agents for the prophylaxis and stherapy of HIV
 infections have focused on the inhibition of the reverse transcriptase or
 some other enzyme of the HIV-1 virus such as, for example, protease.
 Thereby a specific inhibition of viral replication in contrast to cellular
 replication is intended to be accomplished. Nevertheless, the antiviral
 agents of prior art suffer from the drawback that they are accompanied by
 a relatively high toxicity towards the cells, i.e. they do not only affect
 the virus.
 Those groups of substances which have been identified as being active
 against HIV viruses include, inter alia, various nucleoside analogues
 (azidothymidine, di-deoxyinosine and di-deoxycytidine). However, a massive
 formation of resistence of the virus has been detected after some
 relatively short periods of therapy with these substances {Zimmermann et
 al., Abstract No. 3656, IV International Conference on AIDS, Stockholm,
 1988, Rubsamen-Waigmann et al., Infection 19, Suppl. 2, 77-82, 1991}.
 Furthermore, all of the substances mentioned produce considerable
 side-effects, at least when applied in higher doses.
 Another inhibitor of reverse transcriptase is the substance Suramin.
 However, this substance, due to its toxicity towards the mammal organism,
 is also not suitable for prophylaxis or therapy of HIV-virus infections
 {H. Mitsuya et al. "Suramin Protection of T-Cells in vitro against
 Infectivity and Cyto-pathic Effect of HTLV-III, Science 226 (1984), pages
 172-174}.
 Further development has led to reverse transcriptase inhibitors which are
 less toxic towards the mammal organism. These include substances such as
 dextran sulfate and pentosan polysulfate, which have proven to display a
 HIV-1-inhibiting effect in vivo, as has been described in DE 36 01 136 and
 in EP 0 293 826.
 In addition to a chemotherapeutic treatment of HIV infections there is
 basically the possibility of a gene therapy or immunotherapy. Gene therapy
 comprises the incorporation of parts of viral nucleic acids in human
 cells, especially in the target cells of the HIV virus, for example the
 CD4-positive cells of the immune system. Then, the viral messenger RNA
 (m-RNA) can be neutralized by the formation of an "antisense" RNA, i.e. an
 RNA complementary to m-RNA, and hence the virus proliferation can be
 terminated. In some other form, oligonucleotides or structures chemical
 related thereto that are complementary to m-RNA can be employed. In
 immunotherapy, antigens are administered after the infection which are
 expected to support the immune response to HIV.
 Meanwhile, the World Health Organization (WHO) estimates a number of at
 least 13 million of HIV-infected people worldwide; no country has been
 left free from infections with HIV-1 or HIV-2 or both viruses at the same
 time. It is urgently necessary to develop a vaccine for protection from
 HIV infections in order to prevent the epidemic from farther spreading.
 Here, and also in immunotherapy, the main problem is the high variability
 of the HIV viruses: a prophylactic inoculation should and must include all
 of the possible virus variants. Epidemiologic investigations in
 combination with the genetic characterization of the viruses produced the
 result that several subtypes do already exist in both virus families
 {Myers et al., Human Retroviruses and AIDS, Los Alamos, 1991; Dietrich et
 al., Nature 342, 948-950, 1989}, which subtypes are significantly
 distinguished from one another with respect to their hereditary
 information to a degree such that one single vaccine will not be capable
 to be active against all variants. Moreover, these subtypes are also
 subject to different geographic distributions.
 The present invention provides three new HIV 1 virus isolates
 HIV-1.sub.D757, HIV-1.sub.D747, HIV-1.sub.D760, which, surprisingly, form
 a further independent subtype of the HIV-1 family and have been recovered
 from three Indian patients who, at the time of virus isolation, did not
 show any typical AIDS symptoms. Furthermore, the invention also includes
 virus isolates of the HIV-1 type which are up to 30%, and preferably up to
 5%, divergent from HIV-1.sub.D757, HIV-1.sub.D747, and HIV-1.sub.D760.
 The virus isolates, in accordance with the regulations according to the
 Budapest Treaty, have been deposited with the European Collection of
 Animal Cell Cultures (ECACC), Porton Down, Salisbury, Wiltshire, United
 Kingdom, on Aug. 27, 1992, under the following Accession Numbers:
 HIV-1.sub.D747 --ECACC V92082718
 HIV-1.sub.D757 --ECACC V92082719
 HIV-1.sub.D760 --ECACC V92082720
 The virus isolates proliferate on fresh mononuclear cells of peripheral
 blood, i.e. lymphocytes and macrophages.
 The invention further provides a vaccine having an activity spectrum
 against this specific HIV-1 subtype.
 The vaccine contains, as the active ingredient, the peptides
 1. MPNGTKSNS SEQ ID NO:7, MPNGTKGNS SEQ ID NO:8, MPNGTKSNL SEQ ID NO:9,
 2. RNEKDLLALDSWKN SEQ ID NO:10,
 combinations comprising said peptides or longer or shorter subpeptides
 thereof being up to 7 amino acids in length.
 Said peptides are derived from the env region of the strains according to
 the invention (cf. FIG. 1). The nucleotide sequences of these viruses in
 the env gene over a range of 1.8 kb are only to 79.4-81.6% homologous with
 viruses of the North American/European subtype and to 78.9-81.2%
 homologous with prototype viruses of the Central African subtype. The
 homology on the amino acid level is 72.1-75.9% and 71.2-74.2%,
 respectively (cf. Table). Thus, these viruses genetically are to be
 classified between these two subtypes and form some further independent
 subtype which is also distinguished from the subtypes found in
 Rwanda/Uganda and in Northern Thailand by genetic equidistance.
 Upon comparison of the amino acid sequences of the env proteins of
 HIV-1.sub.D757, HIV-1.sub.D747, HIV-1.sub.D760 with the consensus
 sequences as derived for all of the HIV env sequences already published,
 there result for the env region two short ranges, in which the three
 Indian sequences are different from all of the other HIV-1 sequences in 7
 of 9 and in 7 of 14 amino acids, respectively (FIG. 1). Peptides from
 these regions are preferably suitable for a vaccine having a specific
 spectrum of activity against the Indian subtype, and particularly so, if
 the vaccine consists of a combination of these peptides.
 The peptides according to the invention are synthetically produced and, if
 advantageous, are chemically modified. These peptides or longer as well as
 shorter subpeptides, down to 7 amino acids in length, thereof are also a
 constituent of this invention, and so are their modified forms.
 Furthermore, the invention also relates to a vaccine which contains, as the
 active ingredient, peptides from variable regions of other genes of
 HIV-1.sub.D757, HIV-1.sub.D747, HIV-1.sub.D760, if the deviation from the
 corresponding sequence of HIV-1 viruses of other subtypes is more than
 30%.
 In the vaccine, there may further be used antigens from the viruses
 according to the invention or peptide combinations or combinations of
 peptides and antigens. More specifically, the use of such antigens or
 peptides is preferred which, within the loop of the coat glycoprotein
 (amino acids 423-450, relative to HIV-1.sub.Lai), is responsible for
 binding to the CD4-receptor, contain a glycosylation site (NXT/S)
 immediately in front of cysteine 450 (HIV-1.sub.Lai). This glycosylation
 site is typical for the Indian viruses HIV-1.sub.D757, HIV-1.sub.D747 and
 HIV-1.sub.D760. The amino acid regions of the HIV-1.sub.D757,
 HIV-1.sub.D747 and HIV-1.sub.D760 that correspond to the amino acids
 423-450 of HIV-1.sub.Lai are amino acids 294-321 of SEQ ID NO:2, amino
 acids 296-323 of SEQ ID NO:4, or amino acids 304-331 of SEQ ID NO:6
 respectively. This glycosylation site has not been encountered among 29
 HIV-1 env-genes that have been sequenced worldwide.
 One preferred embodiment is a vaccine which is employed for prophylaxis
 prior to infections. Another preferred embodiment consists of that the
 vaccine is used as an immunotherapeutic to be employed after the infection
 and also covers the spectrum of variants of this subtype. The vaccine is
 administered either for injection with adjuvant or as an oral, genital or
 rectal form of application, e.g. via nanoparticles.
 Furtheron, the subject matter of the invention comprises a process for
 producing a vaccine against HIV-1 virus infections from the viruses
 HIV-1.sub.D757, HIV-1.sub.D747 and HIV-1.sub.D760 as well as the use of
 these viruses for the production of a vaccine.
 In still one further embodiment, the viruses HIV-1.sub.D757 1
 HIV-1.sub.D747 and HIV-1.sub.D760 are transferred into a suitable host
 animal and allowed to proliferate therein. Then, the antibodies formed,
 after appropriate work-up as also known in the art for other vaccines, are
 used as a passive vaccine against HIV virus infections. As the host
 animals, more particularly, there may be used, suitable types of monkeys,
 but also animals that can be immunized without developing HIV symptoms
 (e.g. rabbits) {Filice et al., Nature 335 (1988), 366-368}.
 Human monoclonal antibodies against HIV-1.sub.D757, HIV-1.sub.D747 and
 HIV-1.sub.D760 are also suitable for producing a vaccine for a protection
 against HIV-1 virus infections of this subtype.
 In a further embodiment, in a suitable vector, DNA from which a RNA
 complementary to the viral m-RNA can be fully or partially transcribed, is
 transfected into human cells of the immune system and, hence, is conveyed
 into man. Thus, the viral m-RNA is competitively excluded from the further
 augmentation cycle. Likewise, synthetic oligonucleotides can be used for
 neutralizing the viral m-RNA.
 In addition to the applications for therapy and vaccine production,
 HIV-1.sub.D757, HIV-.sup.1.sub.D747 and HIV-.sup.1.sub.D760 can also be
 used for differential diagnostics in order to distinguish infections with
 this subtype from other subtypes. For differential diagnostics, selected
 regions of the DNA of HIV-1.sub.D757, HIV-1.sub.D747 and HIV-1.sub.D760
 are utilized which either do not occur at all in the prototype
 HIV-1.sub.Lai or are significantly different therefrom (by more than 30%).
 From these regions, peptides or nucleic acids for diagnostics are prepared
 according to conventional methods (labelling with radioactive isotopes,
 immunofluorescence test, ELISA etc.).
 Therefore, it is also a constituent of this invention to use
 HIV-1.sub.D757, HIV-1.sub.D747 and HIV-1.sub.D760, or antigens, peptides
 or nucleic acids thereof, for the differential diagnostics for
 differentiating between infections with the subtype, characterized by
 HIV-.sup.1.sub.D757, HIV-1.sub.D747 or HIV-1.sub.D760, and infections with
 other HIV-1 subtypes as defined by the prototypes HIV-1.sub.Lai
 (U.S.A./Europe) HIV-1.sub.Mal (Central Africa), HIV-1.sub.u455
 (Uganda/Rwanda) and Northern Thailand.
 It is also possible to employ peptide residues or PCR tests based on
 HIV-1.sub.D757, HIV-1.sub.D747 or HIV-1.sub.D760, by means of which
 distinction can be made between viruses of this subtypes from other
 HIV-viruses.

Hereinbelow, the Figures and the Table are described:
 The Table shows the nucleotide and amino acid sequence homology between
 HIV-1.sub.D757, HIV-1.sub.D747 or HIV-1.sub.D760 and other HIV-1 virus
 subtypes in percent. The sequences were compared by using Mikrogenie.TM.
 sequencing software by the company Beckman.
 Table 2 shows the amino acid sequences in single character notation of the
 three Indian env clones in comparison to the corresponding sections of
 other subtypes. Highlighted are the two peptides 1 and 2, in which the
 Indian subtype is mainly different from the other sequences, and the
 additional glycolisation site (underlined) in immediate vicinity to the
 CD4 binding domain.
 (-) denotes identical amino acids;
 (.) denotes missing aminoacids.
 Table 3 shows the relation of the sequences HIV-1.sub.D757, HIV-1.sub.D747
 or HIV-1.sub.D760 to the remaining viruses in the phylogenetic tree of the
 viruses. This tree was established with the use of PAUP {Smith, T. F. et
 al., Nature 333, 573-575 (1988)} and the Version 3.21 of the PHYLIP
 bootstrappin algorithm.
 TABLE 1
 Homology of Indian HIV-1 isolates and American/European or prototypical
 African HIV-1
 sequences (1.8 kb PCR-fragment, corresponding to positions 6129-7976 of
 HIV-1.sub.Lai)
 HIV-1 Lai SF2 Eli Mal SIVepz
 D757 79.7 (75.7) 81.6 (75.9) 81.2 (74.2) 80.6 (73.7) 66.1
 (61.2)
 D747 79.4 (73.5) 80.9 (75.6) 80.7 (72.8) 78.9 (73.2) 65.8
 (63.2)
 D760 80.7 (72.1) 81.4 (73.6) 80.9 (71.2) 80.2 (71.7) 66.1
 (61.0)
 Lai 90.0 (84.1) 83.7 (76.2) 82.8 (74.3) 65.0
 (60.1)
 SF2 83.8 (75.6) 82.8 (74.6) 64.3
 (62.0)
 Eli 85.2 (76.9) 65.7
 (61.9)
 Mal 66.4
 (63.2)
 TABLE 2
 HIV-1.sub.Bru
 ------------------S-K--DLGNATN-NSSN.TNSSSGEMMMEKG--------IS-
 HIV-1.sub.SF2 -----------------------DLGKATN-NSSN.WKEEI......KG--------I--
 HIV-1.sub.D757
 SLWDQSLKPCVKLTPLCVTLNCTNA...NVTYDN..........GNYTEEIKNCSFNTTT
 HIV-1.sub.D747
 --------------------H----TYS-S--NS..........T.-N------------
 HIV-1.sub.D760
 --------------------E-G-VNAT-I-NNGE...NNPTNIT--R------P--A--
 HIV-1.sub.Eli ----------------------SD-...ELRNNGTMGNNVTTEEK....GM------V--
 HIV-1.sub.Mal ------------------------VNGTA-NGT-AGSNRTNAELKMEIG-V------I-P
 SIVcpz --------------------Q-SK-NFSQA.......KNLTNQTSSPPL-M------V--
 HIV-1.sub.Bru SI-GKV--EY-F-----II-I-NDTT-.....-T-TS----V----------E-------
 HIV-1.sub.SF2 SI--KI--EN---RN-----I-NASTTTNYTN----H--R-V----------E-------
 HIV-1.sub.D757
 ELRDQKQKVAALFYKLDVVPLDGNDNSS....YRLINCNTSAITQACPKVSFDPIPIHYC
 HIV-1.sub.D747
 ----K----Q-----------NTT----....----------------------------
 HIV-1.sub.D760
 -I--RQ---Y----R--I----N-N--T....------------------T---------
 HIV-1.sub.Eli V-K-K--Q-Y----R--I--I-NDSSTNS.TN--------------------E-------
 HIV-1.sub.Mal VGS-KR-E.Y-T--N--L-QI-D...-DN.SS---------V--------T---------
 SIVcpz ----K-KQ-YS---VE---N-GNEN-T.....--I-----T--------T--E-------
 HIV-1.sub.Bru ----F----------------T----VQ-----R---------------E-VV---A-FT
 HIV-1.sub.SF2 T---F------------K---T----VQ-----R-I-------------E-VV---D-FT
 HIV-1.sub.D757
 APAGYAILKCNNKTFNGTGPCHNVSTRTCTHGIKPVVSTQLLLNGSLAEGEIIIRSENLA
 HIV-1.sub.D747
 -G---------------------I--VQ-------------------------------T
 HIV-1.sub.D760
 --------------------------VQ-----S-------------------------T
 HIV-1.sub.Eli ----F-----RD-K-------T----VQ-----R---------------E-V-------T
 HIV-1.sub.Mal ----F------D-K----EI-K----VQ---------------------E--M------T
 SIVcpz ----F------D-D-S-K-K-T----VH---------T----I-------N-TV-V--KS
 HIV-1.sub.Bru D-A-----Q-----E-N--------------QR---RA-VTI-K-.-NM--------RA-
 HIV-1.sub.SF2 --A-----Q--E--A-N------------Y-..---RA-HT--R------K------RAQ
 HIV-1.sub.D757
 NNVKTIIVHLNQSVRIVCTRPNNNTRKSIRI..GPGQTFYATGDIIGDIRQAHCNISEGK
 HIV-1.sub.D747
 --------------E--Y---------GV--..---Q--------------------KH-
 HIV-1.sub.D760
 D-------------EV---------------..---Q---------------------D-
 HIV-1.sub.Eli --A-N--A---E--K-T-A--YQ---QRTP-..-L--SL-T-R.SRSI-G-------RAQ
 HIV-1.sub.Mal D-T-N---Q--ET-T-N----G----RG-HF..----AL-T--.-V----R-Y-T-N-TE
 SIVcpz K-TDVW--Q-VEA-SLN-H--G----GEVQ-..---M---NIENVV--T-S-Y-K-NGTT
 HIV-1.sub.Bru --A--KQIAS--R-Q-G-N--.-I-KQ----DP--V------G-------STQ-----WF
 HIV-1.sub.SF2 --N--EQIV---R-Q-G-N--.-V-NQ----DP--VM--------------TQLF.....
 HIV-1.sub.D757
 WNETLQRVGKKLAEYFPN.KT.IKFASSSGGGLEITTHSFNCRGEFFYCNTSNLFNSTY.
 HIV-1.sub.D747
 --------------H---.--.-R-------D--------------------D---G--.
 HIV-1.sub.D760
 --------------H---.--.----A----D-----Y--------------G---G--.
 HIV-1.sub.Eli -SK---Q-AR--GTLL.-KTI.---KP----DP---------G---------G-----WN
 HIV-1.sub.Mal -DK---Q-AV--GSLL.-KTK.-I-N-----DP-------------------K-----WQ
 SIVcpz --R-VEE-K-A--TSSNRTAAN-TLNRA---DP-V-H-M---G---------QI-.....
 HIV-1.sub.Bru NSTWSTEGSNNTEGSD---LP-----F--------K-------S-Q-R-S--------T-
 HIV-1.sub.SF2 NNTWRLNHTEGTKG-D--ILP--------------K-------G-Q-S-S--------T-
 HIV-1.sub.D757
 .....MPNGTKGNSNSTITIQCRIKQIINMWQEVGRAMYAPPIEGNITCESNITGLLLVR
 HIV-1.sub.D747
 .....------S--S-----P----------------------A-----K-----I----
 HIV-1.sub.D760
 .....------S-L------P------V-L------------FAR----K----------
 HIV-1.sub.Eli ISAWNNITESNNST-TN--L--------K-.VAGRK-I------R--L-S--------T-
 HIV-1.sub.Mal NNG.ARLSNSTESTG-.--LP-----------KT-K-------A-V-N-L------I-T-
 SIVcpz .........-DNIT-GI-ILP---R--VSS-MR---GI-----R-----N--------TS
 HIV-1.sub.Bru ---NN.--G.S-I---------D------------K-E-------K------....Q---
 HIV-1.sub.SF2 ----NVT-D.T-V---------D-----------IK-E---I---K------....Q---
 HIV-1.sub.D757
 DGGTESNNT..ETFRPGGG-MRNNWRSELYKYKVVEIKPLGVAPTTAKRRVV....EREK
 HIV-1.sub.D747
 ---IEL-D-KT--------E--D-----------------------------....----
 HIV-1.sub.D760
 ---EDT-D..T-I-S-------D-----------------------------....----
 HIV-1.sub.Eli ---..I--STN-----------D------------Q-E-------R------....----
 HIV-1.sub.Mal ---NS-D-SDN--L--------D--I---------R-E-------K------....----
 SIVcpz -TPVTN-SGNL.----T--N-KDI-----------R-E--S----K-R-HT-ARQKD-Q-
 HIV-1.sub.Bru -----.---L--------------R-------------------N---------------
 HIV-1.sub.SF2 -----V--M--------------V-L------------------N---------------
 HIV-1.sub.D757
 RAVGI.GAVFLGFLGAAGSTMGAASMTLTVQARQLLSGIVQQQSNLLRAIEAQQHLLQLT
 HIV-1.sub.D747
 -----.---------------------V--------------------------------
 HIV-1.sub.D760
 ----L.-------------------I----------------------------------
 HIV-1.sub.Eli --I-L.--M--------------R-V---------M-------N----------------
 HIV-1.sub.Mal --I-L.--M----------------L-----------------N----------------
 SIVcpz --AFGL--L---------------AV-----------------N---K-----------S
 HIV-1.sub.Bru --------A-I--V--------------C--------A----A---.-K-LEQ-------
 HIV-1.sub.SF2 --------A----V----R---------C--------A----A---.-K-LED-------
 HIV-1.sub.D757
 VWGIKQLQTRVLAIERYLKDQQLLGIWGRSGKLICTTNVPWNSSWS.NRSQTDIWDNMTW
 HIV-1.sub.D747
 I-------A----------E--------C--------T--------.-------------
 HIV-1.sub.D760
 -------------------------M--C--------A--------.-------------
 HIV-1.sub.Eli --------A-I--V--------------C---H-------------.---LNE--Q----
 HIV-1.sub.Mal --------A----V----Q--R---M--C---H----F--------.---LD---N----
 SIVcpz I--V----A-L--V----Q---I--L--C---AV-Y-T-------PGSN-TD---G-L--
 HIV-1.sub.Bru -E---........................................--N---SL-HS-I-E
 HIV-1.sub.SF2 ---E-........................................--D---N---T---E
 HIV-1.sub.D757
 MQWDR........................................EISNYTDTIYRLLED
 HIV-1.sub.D747
 -----........................................------E--------
 HIV-1.sub.D760
 -----........................................------N--------
 HIV-1.sub.Eli -E-E-........................................--D---GL--S-I-E
 HIV-1.sub.Mal ---EK........................................------GI--N-I-E
 SIVcpz Q---KLVSNYTGKIFGLLEEAQSQQEKNERDLLELDQWASLWNWFD-T---GK-FG---E
 HIV-1.sub.Bru ------K--QE--E--K-AS-----N------------------V--R-V----------
 HIV-1.sub.SF2 ------K--QE--E--K-AS------------------------V--R-V----------
 HIV-1.sub.D757
 SQNQQERNEKDLLALDSWKNLWNWFSITNWLWYIKIFIMIVGGLIGLKIIFAVLSIVNRV
 HIV-1.sub.D747
 --------------------------------------I--------R------C-----
 HIV-1.sub.D760
 -----------------------------------------------R------------
 HIV-1.sub.Eli --T---K---E--E--K-AS--------Q-----------I------R-V-----L----
 HIV-1.sub.Mal --I---K---E--E--K-AS-------SK-----R---IV-------R-------L----
 SIVcpz A-S---K--R---E--Q-AS-----D--K--------L-A---I---R--MT-F-V-R--
 HIV-1.sub.Bru ----------- SEQ ID NO: 11
 HIV-1.sub.SF2 ----------- SEQ ID NO: 12
 HIV-1.sub.D757 RQGYSPLSFQT SEQ ID NO: 2
 HIV-1.sub.D747 KA--------- SEQ ID NO: 4
 HIV-1.sub.D760 ----------- SEQ ID NO: 6
 HIV-1.sub.Eli ----------- SEQ ID NO: 13
 HIV-1.sub.Mal --------L-- SEQ ID NO: 14
 SIVcpz --------L-- SEQ ID NO: 15
 TABLE 3
 ##STR1##
 SEQUENCE LISTING
 &lt;100&gt; GENERAL INFORMATION:
 &lt;160&gt; NUMBER OF SEQ ID NOS: 15
 &lt;200&gt; SEQUENCE CHARACTERISTICS:
 &lt;210&gt; SEQ ID NO 1
 &lt;211&gt; LENGTH: 1932
 &lt;212&gt; TYPE: DNA
 &lt;213&gt; ORGANISM: Human immunodeficiency virus
 &lt;220&gt; FEATURE:
 &lt;223&gt; OTHER INFORMATION: HIV-1(D757)
 &lt;400&gt; SEQUENCE: 1
 c agt tta tgg gat caa agc cta aag cca tgt gta aag ttg acc cca ctc 49
 Ser Leu Trp Asp Gln Ser Leu Lys Pro Cys Val Lys Leu Thr Pro Leu
 1 5 10 15
 tgt gtc act tta aat tgt aca aat gca aat gtt acc tat gat aat ggt 97
 Cys Val Thr Leu Asn Cys Thr Asn Ala Asn Val Thr Tyr Asp Asn Gly
 20 25 30
 aac tac act gaa gaa ata aaa aat tgc tct ttc aat aca act aca gaa 145
 Asn Tyr Thr Glu Glu Ile Lys Asn Cys Ser Phe Asn Thr Thr Thr Glu
 35 40 45
 cta aga gat cag aaa cag aaa gtt gct gca ctt ttt tat aaa ctt gat 193
 Leu Arg Asp Gln Lys Gln Lys Val Ala Ala Leu Phe Tyr Lys Leu Asp
 50 55 60
 gta gta cca ctt gat ggt aat gat aac tct agt tat aga tta ata aat 241
 Val Val Pro Leu Asp Gly Asn Asp Asn Ser Ser Tyr Arg Leu Ile Asn
 65 70 75 80
 tgt aat acc tca gcc ata aca caa gcc tgt cca aag gtc tct ttt gac 289
 Cys Asn Thr Ser Ala Ile Thr Gln Ala Cys Pro Lys Val Ser Phe Asp
 85 90 95
 cca atc cct ata cat tat tgt gct cca gct ggt tat gcg att cta aag 337
 Pro Ile Pro Ile His Tyr Cys Ala Pro Ala Gly Tyr Ala Ile Leu Lys
 100 105 110
 tgt aat aat aag aca ttc aat ggg aca gga cca tgc cat aat gtc agc 385
 Cys Asn Asn Lys Thr Phe Asn Gly Thr Gly Pro Cys His Asn Val Ser
 115 120 125
 aca cgt aca tgt aca cat gga att aag cca gta gta tca act caa cta 433
 Thr Arg Thr Cys Thr His Gly Ile Lys Pro Val Val Ser Thr Gln Leu
 130 135 140
 ctg tta aat ggt agc cta gca gaa gga gag ata ata att aga tct gaa 481
 Leu Leu Asn Gly Ser Leu Ala Glu Gly Glu Ile Ile Ile Arg Ser Glu
 145 150 155 160
 aat ctg gca aac aat gtc aaa aca ata ata gta cat ctt aat caa tct 529
 Asn Leu Ala Asn Asn Val Lys Thr Ile Ile Val His Leu Asn Gln Ser
 165 170 175
 gta aga att gtg tgt aca aga ccc aac aat aat aca aga aaa agt ata 577
 Val Arg Ile Val Cys Thr Arg Pro Asn Asn Asn Thr Arg Lys Ser Ile
 180 185 190
 agg ata gga cca gga caa aca ttc tat gca aca gga gac ata ata gga 625
 Arg Ile Gly Pro Gly Gln Thr Phe Tyr Ala Thr Gly Asp Ile Ile Gly
 195 200 205
 gac ata aga caa gca cat tgt aac att agt gaa ggt aaa tgg aat gaa 673
 Asp Ile Arg Gln Ala His Cys Asn Ile Ser Glu Gly Lys Trp Asn Glu
 210 215 220
 act tta caa agg gta ggt aaa aaa tta gca gaa tac ttc cct aat aaa 721
 Thr Leu Gln Arg Val Gly Lys Lys Leu Ala Glu Tyr Phe Pro Asn Lys
 225 230 235 240
 aca ata aaa ttt gca tca tcc tca gga ggg ggc cta gaa att aca aca 769
 Thr Ile Lys Phe Ala Ser Ser Ser Gly Gly Gly Leu Glu Ile Thr Thr
 245 250 255
 cat agc ttt aat tgt aga gga gaa ttt ttc tat tgc aat aca tca aac 817
 His Ser Phe Asn Cys Arg Gly Glu Phe Phe Tyr Cys Asn Thr Ser Asn
 260 265 270
 ctg ttt aat agt aca tac atg cct aat ggt aca aaa ggt aat tca aac 865
 Leu Phe Asn Ser Thr Tyr Met Pro Asn Gly Thr Lys Gly Asn Ser Asn
 275 280 285
 tca acc atc aca atc caa tgc aga ata aaa caa att ata aac atg tgg 913
 Ser Thr Ile Thr Ile Gln Cys Arg Ile Lys Gln Ile Ile Asn Met Trp
 290 295 300
 cag gag gta gga cga gca atg tat gcc cct ccc att gaa gga aac ata 961
 Gln Glu Val Gly Arg Ala Met Tyr Ala Pro Pro Ile Glu Gly Asn Ile
 305 310 315 320
 acg tgt gaa tcc aat atc aca gga cta cta ttg gta cgt gat gga gga 1009
 Thr Cys Glu Ser Asn Ile Thr Gly Leu Leu Leu Val Arg Asp Gly Gly
 325 330 335
 aca gag tca aat aat aca gag aca ttc aga cct gga gga gga gat atg 1057
 Thr Glu Ser Asn Asn Thr Glu Thr Phe Arg Pro Gly Gly Gly Asp Met
 340 345 350
 agg aac aat tgg aga agt gaa tta tat aaa tat aaa gtg gta gaa att 1105
 Arg Asn Asn Trp Arg Ser Glu Leu Tyr Lys Tyr Lys Val Val Glu Ile
 355 360 365
 aag cca ttg gga gta gcg ccc act act gca aaa agg aga gtg gtg gag 1153
 Lys Pro Leu Gly Val Ala Pro Thr Thr Ala Lys Arg Arg Val Val Glu
 370 375 380
 aga gaa aaa aga gca gtg gga ata gga gct gtg ttc ctt ggg ttc ttg 1201
 Arg Glu Lys Arg Ala Val Gly Ile Gly Ala Val Phe Leu Gly Phe Leu
 385 390 395 400
 gga gca gca gga agc act atg ggc gcg gca tca atg acg ctg acg gta 1249
 Gly Ala Ala Gly Ser Thr Met Gly Ala Ala Ser Met Thr Leu Thr Val
 405 410 415
 cag gcc aga caa ttg ttg tct ggt ata gtg caa cag caa agc aat ttg 1297
 Gln Ala Arg Gln Leu Leu Ser Gly Ile Val Gln Gln Gln Ser Asn Leu
 420 425 430
 ctg agg gct ata gag gcg caa cag cat ctg ttg caa ctc acg gtc tgg 1345
 Leu Arg Ala Ile Glu Ala Gln Gln His Leu Leu Gln Leu Thr Val Trp
 435 440 445
 ggc att aag cag ctc cag aca aga gtc ctg gct ata gaa aga tac cta 1393
 Gly Ile Lys Gln Leu Gln Thr Arg Val Leu Ala Ile Glu Arg Tyr Leu
 450 455 460
 aag gat caa cag ctc cta ggg att tgg ggc cgc tct gga aaa ctc atc 1441
 Lys Asp Gln Gln Leu Leu Gly Ile Trp Gly Arg Ser Gly Lys Leu Ile
 465 470 475 480
 tgc acc act aat gta cct tgg aac tcc agc tgg agt aac aga tct caa 1489
 Cys Thr Thr Asn Val Pro Trp Asn Ser Ser Trp Ser Asn Arg Ser Gln
 485 490 495
 aca gat att tgg gat aac atg acc tgg atg cag tgg gat aga gaa att 1537
 Thr Asp Ile Trp Asp Asn Met Thr Trp Met Gln Trp Asp Arg Glu Ile
 500 505 510
 agt aat tac aca gac aca ata tac agg ttg ctt gaa gac tcg caa aac 1585
 Ser Asn Tyr Thr Asp Thr Ile Tyr Arg Leu Leu Glu Asp Ser Gln Asn
 515 520 525
 cag cag gaa aga aat gaa aaa gat tta tta gca ttg gac agt tgg aaa 1633
 Gln Gln Glu Arg Asn Glu Lys Asp Leu Leu Ala Leu Asp Ser Trp Lys
 530 535 540
 aat ctg tgg aat tgg ttt agc ata aca aat tgg ctg tgg tat ata aaa 1681
 Asn Leu Trp Asn Trp Phe Ser Ile Thr Asn Trp Leu Trp Tyr Ile Lys
 545 550 555 560
 ata ttc ata atg ata gta gga ggc ttg ata ggt ttg aaa ata att ttt 1729
 Ile Phe Ile Met Ile Val Gly Gly Leu Ile Gly Leu Lys Ile Ile Phe
 565 570 575
 gct gtg ctc tct ata gtg aat aga gtt agg cag gga tac tca cct tta 1777
 Ala Val Leu Ser Ile Val Asn Arg Val Arg Gln Gly Tyr Ser Pro Leu
 580 585 590
 tcg ttt cag acc cttaccccga acccaggggg acccgacagg ctcgaaagaa 1829
 Ser Phe Gln Thr
 595
 tcgaaggagg aggtggagag caagacaaag acagatccat tcgcttagtg aacggattct 1889
 tagcacttgc ctgggacgac tgcggagcct gtgcctcttc agc 1932
 &lt;200&gt; SEQUENCE CHARACTERISTICS:
 &lt;210&gt; SEQ ID NO 2
 &lt;211&gt; LENGTH: 596
 &lt;212&gt; TYPE: PRT
 &lt;213&gt; ORGANISM: Human immunodeficiency virus
 &lt;220&gt; FEATURE:
 &lt;223&gt; OTHER INFORMATION: HIV-1(D757)
 &lt;400&gt; SEQUENCE: 2
 Ser Leu Trp Asp Gln Ser Leu Lys Pro Cys Val Lys Leu Thr Pro Leu
 1 5 10 15
 Cys Val Thr Leu Asn Cys Thr Asn Ala Asn Val Thr Tyr Asp Asn Gly
 20 25 30
 Asn Tyr Thr Glu Glu Ile Lys Asn Cys Ser Phe Asn Thr Thr Thr Glu
 35 40 45
 Leu Arg Asp Gln Lys Gln Lys Val Ala Ala Leu Phe Tyr Lys Leu Asp
 50 55 60
 Val Val Pro Leu Asp Gly Asn Asp Asn Ser Ser Tyr Arg Leu Ile Asn
 65 70 75 80
 Cys Asn Thr Ser Ala Ile Thr Gln Ala Cys Pro Lys Val Ser Phe Asp
 85 90 95
 Pro Ile Pro Ile His Tyr Cys Ala Pro Ala Gly Tyr Ala Ile Leu Lys
 100 105 110
 Cys Asn Asn Lys Thr Phe Asn Gly Thr Gly Pro Cys His Asn Val Ser
 115 120 125
 Thr Arg Thr Cys Thr His Gly Ile Lys Pro Val Val Ser Thr Gln Leu
 130 135 140
 Leu Leu Asn Gly Ser Leu Ala Glu Gly Glu Ile Ile Ile Arg Ser Glu
 145 150 155 160
 Asn Leu Ala Asn Asn Val Lys Thr Ile Ile Val His Leu Asn Gln Ser
 165 170 175
 Val Arg Ile Val Cys Thr Arg Pro Asn Asn Asn Thr Arg Lys Ser Ile
 180 185 190
 Arg Ile Gly Pro Gly Gln Thr Phe Tyr Ala Thr Gly Asp Ile Ile Gly
 195 200 205
 Asp Ile Arg Gln Ala His Cys Asn Ile Ser Glu Gly Lys Trp Asn Glu
 210 215 220
 Thr Leu Gln Arg Val Gly Lys Lys Leu Ala Glu Tyr Phe Pro Asn Lys
 225 230 235 240
 Thr Ile Lys Phe Ala Ser Ser Ser Gly Gly Gly Leu Glu Ile Thr Thr
 245 250 255
 His Ser Phe Asn Cys Arg Gly Glu Phe Phe Tyr Cys Asn Thr Ser Asn
 260 265 270
 Leu Phe Asn Ser Thr Tyr Met Pro Asn Gly Thr Lys Gly Asn Ser Asn
 275 280 285
 Ser Thr Ile Thr Ile Gln Cys Arg Ile Lys Gln Ile Ile Asn Met Trp
 290 295 300
 Gln Glu Val Gly Arg Ala Met Tyr Ala Pro Pro Ile Glu Gly Asn Ile
 305 310 315 320
 Thr Cys Glu Ser Asn Ile Thr Gly Leu Leu Leu Val Arg Asp Gly Gly
 325 330 335
 Thr Glu Ser Asn Asn Thr Glu Thr Phe Arg Pro Gly Gly Gly Asp Met
 340 345 350
 Arg Asn Asn Trp Arg Ser Glu Leu Tyr Lys Tyr Lys Val Val Glu Ile
 355 360 365
 Lys Pro Leu Gly Val Ala Pro Thr Thr Ala Lys Arg Arg Val Val Glu
 370 375 380
 Arg Glu Lys Arg Ala Val Gly Ile Gly Ala Val Phe Leu Gly Phe Leu
 385 390 395 400
 Gly Ala Ala Gly Ser Thr Met Gly Ala Ala Ser Met Thr Leu Thr Val
 405 410 415
 Gln Ala Arg Gln Leu Leu Ser Gly Ile Val Gln Gln Gln Ser Asn Leu
 420 425 430
 Leu Arg Ala Ile Glu Ala Gln Gln His Leu Leu Gln Leu Thr Val Trp
 435 440 445
 Gly Ile Lys Gln Leu Gln Thr Arg Val Leu Ala Ile Glu Arg Tyr Leu
 450 455 460
 Lys Asp Gln Gln Leu Leu Gly Ile Trp Gly Arg Ser Gly Lys Leu Ile
 465 470 475 480
 Cys Thr Thr Asn Val Pro Trp Asn Ser Ser Trp Ser Asn Arg Ser Gln
 485 490 495
 Thr Asp Ile Trp Asp Asn Met Thr Trp Met Gln Trp Asp Arg Glu Ile
 500 505 510
 Ser Asn Tyr Thr Asp Thr Ile Tyr Arg Leu Leu Glu Asp Ser Gln Asn
 515 520 525
 Gln Gln Glu Arg Asn Glu Lys Asp Leu Leu Ala Leu Asp Ser Trp Lys
 530 535 540
 Asn Leu Trp Asn Trp Phe Ser Ile Thr Asn Trp Leu Trp Tyr Ile Lys
 545 550 555 560
 Ile Phe Ile Met Ile Val Gly Gly Leu Ile Gly Leu Lys Ile Ile Phe
 565 570 575
 Ala Val Leu Ser Ile Val Asn Arg Val Arg Gln Gly Tyr Ser Pro Leu
 580 585 590
 Ser Phe Gln Thr
 595
 &lt;200&gt; SEQUENCE CHARACTERISTICS:
 &lt;210&gt; SEQ ID NO 3
 &lt;211&gt; LENGTH: 1944
 &lt;212&gt; TYPE: DNA
 &lt;213&gt; ORGANISM: Human immunodeficiency virus
 &lt;220&gt; FEATURE:
 &lt;223&gt; OTHER INFORMATION: HIV-1(D747)
 &lt;400&gt; SEQUENCE: 3
 taatgtctgg gcaacacatg cctgtgtacc cacagacccc aacccacaag agatggtttt 60
 gggaaatgta acagaaaatt ttaacatgtg gagaaatgac atggtgaatc agatgcatga 120
 ggatgtaatc agt tta tgg gat caa agc cta aag cca tgt gta aag ttg 169
 Ser Leu Trp Asp Gln Ser Leu Lys Pro Cys Val Lys Leu
 1 5 10
 acc cca ctc tgt gtc act tta cat tgt aca aat gct acc tat agt aat 217
 Thr Pro Leu Cys Val Thr Leu His Cys Thr Asn Ala Thr Tyr Ser Asn
 15 20 25
 agt acc tac aat agt acc tac aat gaa gaa ata aaa aat tgc tct ttc 265
 Ser Thr Tyr Asn Ser Thr Tyr Asn Glu Glu Ile Lys Asn Cys Ser Phe
 30 35 40 45
 aat aca act acg gaa cta aga gat aag aaa cag aaa gta caa gca ctt 313
 Asn Thr Thr Thr Glu Leu Arg Asp Lys Lys Gln Lys Val Gln Ala Leu
 50 55 60
 ttt tat aaa ctt gat gta gta cca ctt aat act act gat aac tct agt 361
 Phe Tyr Lys Leu Asp Val Val Pro Leu Asn Thr Thr Asp Asn Ser Ser
 65 70 75
 tat aga tta ata aat tgt aat acc tca gcc ata aca caa gcc tgt cca 409
 Tyr Arg Leu Ile Asn Cys Asn Thr Ser Ala Ile Thr Gln Ala Cys Pro
 80 85 90
 aag gtc tca ttt gac cca att cct ata cat tat tgt gct gga gct ggt 457
 Lys Val Ser Phe Asp Pro Ile Pro Ile His Tyr Cys Ala Gly Ala Gly
 95 100 105
 tat gcg att cta aag tgt aat aat aag aca ttc aat ggg aca gga cca 505
 Tyr Ala Ile Leu Lys Cys Asn Asn Lys Thr Phe Asn Gly Thr Gly Pro
 110 115 120 125
 tgc cat aat atc agc aca gta caa tgt aca cat gga att aag cca gta 553
 Cys His Asn Ile Ser Thr Val Gln Cys Thr His Gly Ile Lys Pro Val
 130 135 140
 gta tca act caa cta ctg tta aat ggt agc cta gca gaa gga gag ata 601
 Val Ser Thr Gln Leu Leu Leu Asn Gly Ser Leu Ala Glu Gly Glu Ile
 145 150 155
 ata att aga tct gaa aat ctg aca aac aat gtc aaa aca ata ata gta 649
 Ile Ile Arg Ser Glu Asn Leu Thr Asn Asn Val Lys Thr Ile Ile Val
 160 165 170
 cat ctt aat caa tct gta gaa att gtg tat aca aga ccc aac aat aat 697
 His Leu Asn Gln Ser Val Glu Ile Val Tyr Thr Arg Pro Asn Asn Asn
 175 180 185
 aca agg aaa ggt gta agg ata gga cca gga caa aca ttc tat gca aca 745
 Thr Arg Lys Gly Val Arg Ile Gly Pro Gly Gln Thr Phe Tyr Ala Thr
 190 195 200 205
 gga gac ata ata gga gac ata aga caa gca cat tgt aac att agt aaa 793
 Gly Asp Ile Ile Gly Asp Ile Arg Gln Ala His Cys Asn Ile Ser Lys
 210 215 220
 cat aaa tgg aat gaa act tta caa agg gta ggt aaa aaa tta gca gaa 841
 His Lys Trp Asn Glu Thr Leu Gln Arg Val Gly Lys Lys Leu Ala Glu
 225 230 235
 cac ttc cct aat aaa aca ata aga ttt gca tca tcc tca gga ggg gac 889
 His Phe Pro Asn Lys Thr Ile Arg Phe Ala Ser Ser Ser Gly Gly Asp
 240 245 250
 cta gaa att aca aca cat agc ttt aat tgt aga gga gaa ttt ttc tat 937
 Leu Glu Ile Thr Thr His Ser Phe Asn Cys Arg Gly Glu Phe Phe Tyr
 255 260 265
 tgc aat aca tca gac ctg ttt aat ggt aca tac atg cct aat ggt aca 985
 Cys Asn Thr Ser Asp Leu Phe Asn Gly Thr Tyr Met Pro Asn Gly Thr
 270 275 280 285
 aaa agt aat tca agc tca acc atc aca att cca tgc aga ata aaa caa 1033
 Lys Ser Asn Ser Ser Ser Thr Ile Thr Ile Pro Cys Arg Ile Lys Gln
 290 295 300
 att ata aac atg tgg cag gag gta gga cga gca atg tat gcc cct ccc 1081
 Ile Ile Asn Met Trp Gln Glu Val Gly Arg Ala Met Tyr Ala Pro Pro
 305 310 315
 att gca gga aac ata acg tgt aaa tcc aat att aca gga ata cta ttg 1129
 Ile Ala Gly Asn Ile Thr Cys Lys Ser Asn Ile Thr Gly Ile Leu Leu
 320 325 330
 gta cgt gat gga gga ata gag cta aat gat aca aag aca gag aca ttc 1177
 Val Arg Asp Gly Gly Ile Glu Leu Asn Asp Thr Lys Thr Glu Thr Phe
 335 340 345
 aga ccg gga gga gga gaa atg agg gac aat tgg aga agt gaa tta tat 1225
 Arg Pro Gly Gly Gly Glu Met Arg Asp Asn Trp Arg Ser Glu Leu Tyr
 350 355 360 365
 aaa tat aaa gtg gta gaa att aag cca ttg gga gta gcg ccc act act 1273
 Lys Tyr Lys Val Val Glu Ile Lys Pro Leu Gly Val Ala Pro Thr Thr
 370 375 380
 gca aaa agg aga gtg gtg gag aga gaa aaa aga gca gtg gga ata gga 1321
 Ala Lys Arg Arg Val Val Glu Arg Glu Lys Arg Ala Val Gly Ile Gly
 385 390 395
 gct gta ttc ctt ggg ttc ttg gga gca gca gga agc act atg ggc gcg 1369
 Ala Val Phe Leu Gly Phe Leu Gly Ala Ala Gly Ser Thr Met Gly Ala
 400 405 410
 gcg tca atg acc gtg acg gta cag gcc aga caa ttg ttg tct ggt ata 1417
 Ala Ser Met Thr Val Thr Val Gln Ala Arg Gln Leu Leu Ser Gly Ile
 415 420 425
 gtg caa cag caa agc aat ttg ctg agg gct ata gag gcg caa cag cat 1465
 Val Gln Gln Gln Ser Asn Leu Leu Arg Ala Ile Glu Ala Gln Gln His
 430 435 440 445
 ctg ttg caa ctc acg atc tgg ggg att aag cag ctc cag gca aga gtc 1513
 Leu Leu Gln Leu Thr Ile Trp Gly Ile Lys Gln Leu Gln Ala Arg Val
 450 455 460
 ctg gct ata gaa aga tac cta aag gaa caa cag ctc cta ggg att tgg 1561
 Leu Ala Ile Glu Arg Tyr Leu Lys Glu Gln Gln Leu Leu Gly Ile Trp
 465 470 475
 ggc tgc tct gga aaa ctc atc tgc acc act act gta cct tgg aac tcc 1609
 Gly Cys Ser Gly Lys Leu Ile Cys Thr Thr Thr Val Pro Trp Asn Ser
 480 485 490
 agt tgg agt aac aga tct caa aca gat att tgg gat aac atg acc tgg 1657
 Ser Trp Ser Asn Arg Ser Gln Thr Asp Ile Trp Asp Asn Met Thr Trp
 495 500 505
 atg cag tgg gat aga gaa att agt aat tac aca gaa aca ata tac agg 1705
 Met Gln Trp Asp Arg Glu Ile Ser Asn Tyr Thr Glu Thr Ile Tyr Arg
 510 515 520 525
 ttg ctt gaa gac tcg caa aac cag cag gaa aga aat gaa aaa gat tta 1753
 Leu Leu Glu Asp Ser Gln Asn Gln Gln Glu Arg Asn Glu Lys Asp Leu
 530 535 540
 tta gca ttg gac agt tgg aaa aat ctg tgg aat tgg ttt agc ata aca 1801
 Leu Ala Leu Asp Ser Trp Lys Asn Leu Trp Asn Trp Phe Ser Ile Thr
 545 550 555
 aat tgg cta tgg tat ata aaa ata ttc ata ata ata gta gga ggc ttg 1849
 Asn Trp Leu Trp Tyr Ile Lys Ile Phe Ile Ile Ile Val Gly Gly Leu
 560 565 570
 ata ggc ttg aga ata att ttt gct gtg ctt tgt ata gta aat aga gtt 1897
 Ile Gly Leu Arg Ile Ile Phe Ala Val Leu Cys Ile Val Asn Arg Val
 575 580 585
 aag gca gga tac tca cct ttg tcg ttt cag acc cttaccccga accc 1944
 Lys Ala Gly Tyr Ser Pro Leu Ser Phe Gln Thr
 590 595 600
 &lt;200&gt; SEQUENCE CHARACTERISTICS:
 &lt;210&gt; SEQ ID NO 4
 &lt;211&gt; LENGTH: 600
 &lt;212&gt; TYPE: PRT
 &lt;213&gt; ORGANISM: Human immunodeficiency virus
 &lt;220&gt; FEATURE:
 &lt;223&gt; OTHER INFORMATION: HIV-1(D747)
 &lt;400&gt; SEQUENCE: 4
 Ser Leu Trp Asp Gln Ser Leu Lys Pro Cys Val Lys Leu Thr Pro Leu
 1 5 10 15
 Cys Val Thr Leu His Cys Thr Asn Ala Thr Tyr Ser Asn Ser Thr Tyr
 20 25 30
 Asn Ser Thr Tyr Asn Glu Glu Ile Lys Asn Cys Ser Phe Asn Thr Thr
 35 40 45
 Thr Glu Leu Arg Asp Lys Lys Gln Lys Val Gln Ala Leu Phe Tyr Lys
 50 55 60
 Leu Asp Val Val Pro Leu Asn Thr Thr Asp Asn Ser Ser Tyr Arg Leu
 65 70 75 80
 Ile Asn Cys Asn Thr Ser Ala Ile Thr Gln Ala Cys Pro Lys Val Ser
 85 90 95
 Phe Asp Pro Ile Pro Ile His Tyr Cys Ala Gly Ala Gly Tyr Ala Ile
 100 105 110
 Leu Lys Cys Asn Asn Lys Thr Phe Asn Gly Thr Gly Pro Cys His Asn
 115 120 125
 Ile Ser Thr Val Gln Cys Thr His Gly Ile Lys Pro Val Val Ser Thr
 130 135 140
 Gln Leu Leu Leu Asn Gly Ser Leu Ala Glu Gly Glu Ile Ile Ile Arg
 145 150 155 160
 Ser Glu Asn Leu Thr Asn Asn Val Lys Thr Ile Ile Val His Leu Asn
 165 170 175
 Gln Ser Val Glu Ile Val Tyr Thr Arg Pro Asn Asn Asn Thr Arg Lys
 180 185 190
 Gly Val Arg Ile Gly Pro Gly Gln Thr Phe Tyr Ala Thr Gly Asp Ile
 195 200 205
 Ile Gly Asp Ile Arg Gln Ala His Cys Asn Ile Ser Lys His Lys Trp
 210 215 220
 Asn Glu Thr Leu Gln Arg Val Gly Lys Lys Leu Ala Glu His Phe Pro
 225 230 235 240
 Asn Lys Thr Ile Arg Phe Ala Ser Ser Ser Gly Gly Asp Leu Glu Ile
 245 250 255
 Thr Thr His Ser Phe Asn Cys Arg Gly Glu Phe Phe Tyr Cys Asn Thr
 260 265 270
 Ser Asp Leu Phe Asn Gly Thr Tyr Met Pro Asn Gly Thr Lys Ser Asn
 275 280 285
 Ser Ser Ser Thr Ile Thr Ile Pro Cys Arg Ile Lys Gln Ile Ile Asn
 290 295 300
 Met Trp Gln Glu Val Gly Arg Ala Met Tyr Ala Pro Pro Ile Ala Gly
 305 310 315 320
 Asn Ile Thr Cys Lys Ser Asn Ile Thr Gly Ile Leu Leu Val Arg Asp
 325 330 335
 Gly Gly Ile Glu Leu Asn Asp Thr Lys Thr Glu Thr Phe Arg Pro Gly
 340 345 350
 Gly Gly Glu Met Arg Asp Asn Trp Arg Ser Glu Leu Tyr Lys Tyr Lys
 355 360 365
 Val Val Glu Ile Lys Pro Leu Gly Val Ala Pro Thr Thr Ala Lys Arg
 370 375 380
 Arg Val Val Glu Arg Glu Lys Arg Ala Val Gly Ile Gly Ala Val Phe
 385 390 395 400
 Leu Gly Phe Leu Gly Ala Ala Gly Ser Thr Met Gly Ala Ala Ser Met
 405 410 415
 Thr Val Thr Val Gln Ala Arg Gln Leu Leu Ser Gly Ile Val Gln Gln
 420 425 430
 Gln Ser Asn Leu Leu Arg Ala Ile Glu Ala Gln Gln His Leu Leu Gln
 435 440 445
 Leu Thr Ile Trp Gly Ile Lys Gln Leu Gln Ala Arg Val Leu Ala Ile
 450 455 460
 Glu Arg Tyr Leu Lys Glu Gln Gln Leu Leu Gly Ile Trp Gly Cys Ser
 465 470 475 480
 Gly Lys Leu Ile Cys Thr Thr Thr Val Pro Trp Asn Ser Ser Trp Ser
 485 490 495
 Asn Arg Ser Gln Thr Asp Ile Trp Asp Asn Met Thr Trp Met Gln Trp
 500 505 510
 Asp Arg Glu Ile Ser Asn Tyr Thr Glu Thr Ile Tyr Arg Leu Leu Glu
 515 520 525
 Asp Ser Gln Asn Gln Gln Glu Arg Asn Glu Lys Asp Leu Leu Ala Leu
 530 535 540
 Asp Ser Trp Lys Asn Leu Trp Asn Trp Phe Ser Ile Thr Asn Trp Leu
 545 550 555 560
 Trp Tyr Ile Lys Ile Phe Ile Ile Ile Val Gly Gly Leu Ile Gly Leu
 565 570 575
 Arg Ile Ile Phe Ala Val Leu Cys Ile Val Asn Arg Val Lys Ala Gly
 580 585 590
 Tyr Ser Pro Leu Ser Phe Gln Thr
 595 600
 &lt;200&gt; SEQUENCE CHARACTERISTICS:
 &lt;210&gt; SEQ ID NO 5
 &lt;211&gt; LENGTH: 1952
 &lt;212&gt; TYPE: DNA
 &lt;213&gt; ORGANISM: Human immunodeficiency virus
 &lt;220&gt; FEATURE:
 &lt;223&gt; OTHER INFORMATION: HIV-1(D760)
 &lt;400&gt; SEQUENCE: 5
 cataatgtct gggctacata tgcctgtgta cccacaggcc ccgacccaca agaaatagtt 60
 ttggaaaatg taacaggaaa ttttaacatg tggaaaaatg acatggtgga tcaaatgcat 120
 gaggatgtaa tc agt tta tgg gat caa agc cta aag cca tgt gta aag ttg 171
 Ser Leu Trp Asp Gln Ser Leu Lys Pro Cys Val Lys Leu
 1 5 10
 acc cca ctc tgt gtc act tta gag tgt gga aat gtt aat gct acc aat 219
 Thr Pro Leu Cys Val Thr Leu Glu Cys Gly Asn Val Asn Ala Thr Asn
 15 20 25
 att acc aat aat ggg gaa aat aat cct acc aat att acc aat aat agg 267
 Ile Thr Asn Asn Gly Glu Asn Asn Pro Thr Asn Ile Thr Asn Asn Arg
 30 35 40 45
 gaa gaa ata aaa aat tgc cct ttc aat gca acc aca gaa ata aga gat 315
 Glu Glu Ile Lys Asn Cys Pro Phe Asn Ala Thr Thr Glu Ile Arg Asp
 50 55 60
 agg cag cag aaa gtg tat gca ctt ttt tat aga ctt gat ata gta cca 363
 Arg Gln Gln Lys Val Tyr Ala Leu Phe Tyr Arg Leu Asp Ile Val Pro
 65 70 75
 ctt gat aat aat aat aat agc acc tat aga tta ata aat tgt aat acc 411
 Leu Asp Asn Asn Asn Asn Ser Thr Tyr Arg Leu Ile Asn Cys Asn Thr
 80 85 90
 tca gcc ata aca caa gcc tgt cca aag gtc act ttt gat cca att cct 459
 Ser Ala Ile Thr Gln Ala Cys Pro Lys Val Thr Phe Asp Pro Ile Pro
 95 100 105
 ata cac tat tgt gct cca gct ggt tat gcg att cta aag tgt aat aat 507
 Ile His Tyr Cys Ala Pro Ala Gly Tyr Ala Ile Leu Lys Cys Asn Asn
 110 115 120 125
 aag aca ttc aat ggg aca gga cca tgc cat aat gtc agc aca gta caa 555
 Lys Thr Phe Asn Gly Thr Gly Pro Cys His Asn Val Ser Thr Val Gln
 130 135 140
 tgt aca cat gga att agc cca gtg gta tca act caa cta ctg tta aat 603
 Cys Thr His Gly Ile Ser Pro Val Val Ser Thr Gln Leu Leu Leu Asn
 145 150 155
 ggt agc cta gca gaa gga gag ata ata att aga tct gaa aat ctg aca 651
 Gly Ser Leu Ala Glu Gly Glu Ile Ile Ile Arg Ser Glu Asn Leu Thr
 160 165 170
 gac aat gtc aaa aca ata ata gta cat ctt aat caa tct gta gaa gtt 699
 Asp Asn Val Lys Thr Ile Ile Val His Leu Asn Gln Ser Val Glu Val
 175 180 185
 gtg tgt aca aga ccc aac aat aat aca aga aaa agt ata agg ata gga 747
 Val Cys Thr Arg Pro Asn Asn Asn Thr Arg Lys Ser Ile Arg Ile Gly
 190 195 200 205
 cca gga caa aca ttt tat gca aca gga gac ata ata gga gac ata aga 795
 Pro Gly Gln Thr Phe Tyr Ala Thr Gly Asp Ile Ile Gly Asp Ile Arg
 210 215 220
 caa gca cat tgt aac att agt gaa gat aaa tgg aat gaa act tta caa 843
 Gln Ala His Cys Asn Ile Ser Glu Asp Lys Trp Asn Glu Thr Leu Gln
 225 230 235
 agg gta ggt aaa aaa cta gca gaa cac ttc cct aat aaa aca ata aaa 891
 Arg Val Gly Lys Lys Leu Ala Glu His Phe Pro Asn Lys Thr Ile Lys
 240 245 250
 ttt gca gca tcc tca gga ggg gac cta gaa att aca aca tat agt ttt 939
 Phe Ala Ala Ser Ser Gly Gly Asp Leu Glu Ile Thr Thr Tyr Ser Phe
 255 260 265
 aat tgt aga gga gaa ttt ttc tat tgc aat aca tca ggc ctg ttc aat 987
 Asn Cys Arg Gly Glu Phe Phe Tyr Cys Asn Thr Ser Gly Leu Phe Asn
 270 275 280 285
 ggt aca tac atg cct aat ggt aca aaa agt aat tta aac tca acc atc 1035
 Gly Thr Tyr Met Pro Asn Gly Thr Lys Ser Asn Leu Asn Ser Thr Ile
 290 295 300
 aca atc cca tgc aga ata aaa caa att gtg aac ctg tgg cag gag gta 1083
 Thr Ile Pro Cys Arg Ile Lys Gln Ile Val Asn Leu Trp Gln Glu Val
 305 310 315
 gga cga gca atg tat gcc cct cca ttt gcc agg aac ata aca tgt aaa 1131
 Gly Arg Ala Met Tyr Ala Pro Pro Phe Ala Arg Asn Ile Thr Cys Lys
 320 325 330
 tca aat atc aca gga cta cta ttg gta cgt gat gga gga gaa gac aca 1179
 Ser Asn Ile Thr Gly Leu Leu Leu Val Arg Asp Gly Gly Glu Asp Thr
 335 340 345
 aat gat aca gag ata ttc agt cct gga gga gga gat atg agg gac aat 1227
 Asn Asp Thr Glu Ile Phe Ser Pro Gly Gly Gly Asp Met Arg Asp Asn
 350 355 360 365
 tgg aga agt gaa tta tac aaa tat aaa gtg gta gaa att aag cca ttg 1275
 Trp Arg Ser Glu Leu Tyr Lys Tyr Lys Val Val Glu Ile Lys Pro Leu
 370 375 380
 gga gta gca ccc act aca gca aaa agg aga gtg gtg gag aga gaa aaa 1323
 Gly Val Ala Pro Thr Thr Ala Lys Arg Arg Val Val Glu Arg Glu Lys
 385 390 395
 aga gca gtg gga tta gga gct gtg ttc ctt ggg ttc ttg gga gca gca 1371
 Arg Ala Val Gly Leu Gly Ala Val Phe Leu Gly Phe Leu Gly Ala Ala
 400 405 410
 gga agc act atg ggc gcg gcg tca ata acg ctg acg gta cag gcc aga 1419
 Gly Ser Thr Met Gly Ala Ala Ser Ile Thr Leu Thr Val Gln Ala Arg
 415 420 425
 caa tta ctg tct ggt ata gtg caa cag caa agc aat ttg ctg agg gct 1467
 Gln Leu Leu Ser Gly Ile Val Gln Gln Gln Ser Asn Leu Leu Arg Ala
 430 435 440 445
 ata gag gcg caa cag cat ctg ttg caa ctc acg gtc tgg ggc att aag 1515
 Ile Glu Ala Gln Gln His Leu Leu Gln Leu Thr Val Trp Gly Ile Lys
 450 455 460
 cag ctc cag aca aga gtc ctg gct ata gaa aga tac cta aag gat caa 1563
 Gln Leu Gln Thr Arg Val Leu Ala Ile Glu Arg Tyr Leu Lys Asp Gln
 465 470 475
 cag ctc cta ggg atg tgg ggc tgc tct gga aaa ctc atc tgc acc act 1611
 Gln Leu Leu Gly Met Trp Gly Cys Ser Gly Lys Leu Ile Cys Thr Thr
 480 485 490
 gct gta cct tgg aac tcc agt tgg agt aac aga tct caa aca gat att 1659
 Ala Val Pro Trp Asn Ser Ser Trp Ser Asn Arg Ser Gln Thr Asp Ile
 495 500 505
 tgg gat aac atg acc tgg atg cag tgg gat agg gaa att agt aat tac 1707
 Trp Asp Asn Met Thr Trp Met Gln Trp Asp Arg Glu Ile Ser Asn Tyr
 510 515 520 525
 aca aat aca ata tac agg ttg ctt gaa gac tcg caa aac cag cag gaa 1755
 Thr Asn Thr Ile Tyr Arg Leu Leu Glu Asp Ser Gln Asn Gln Gln Glu
 530 535 540
 aga aat gaa aaa gat tta tta gca ttg gac agt tgg aaa aat ctg tgg 1803
 Arg Asn Glu Lys Asp Leu Leu Ala Leu Asp Ser Trp Lys Asn Leu Trp
 545 550 555
 aat tgg ttt agc ata aca aat tgg ctg tgg tat ata aaa ata ttc ata 1851
 Asn Trp Phe Ser Ile Thr Asn Trp Leu Trp Tyr Ile Lys Ile Phe Ile
 560 565 570
 atg ata gta gga ggc ttg ata ggt ttg aga ata att ttt gct gtg ctc 1899
 Met Ile Val Gly Gly Leu Ile Gly Leu Arg Ile Ile Phe Ala Val Leu
 575 580 585
 tct ata gtg aat aga gtt agg cag gga tac tca cct ttg tcg ttt cag 1947
 Ser Ile Val Asn Arg Val Arg Gln Gly Tyr Ser Pro Leu Ser Phe Gln
 590 595 600 605
 acc ct 1952
 Thr
 &lt;200&gt; SEQUENCE CHARACTERISTICS:
 &lt;210&gt; SEQ ID NO 6
 &lt;211&gt; LENGTH: 606
 &lt;212&gt; TYPE: PRT
 &lt;213&gt; ORGANISM: Human immunodeficiency virus
 &lt;220&gt; FEATURE:
 &lt;223&gt; OTHER INFORMATION: HIV-1(D760)
 &lt;400&gt; SEQUENCE: 6
 Ser Leu Trp Asp Gln Ser Leu Lys Pro Cys Val Lys Leu Thr Pro Leu
 1 5 10 15
 Cys Val Thr Leu Glu Cys Gly Asn Val Asn Ala Thr Asn Ile Thr Asn
 20 25 30
 Asn Gly Glu Asn Asn Pro Thr Asn Ile Thr Asn Asn Arg Glu Glu Ile
 35 40 45
 Lys Asn Cys Pro Phe Asn Ala Thr Thr Glu Ile Arg Asp Arg Gln Gln
 50 55 60
 Lys Val Tyr Ala Leu Phe Tyr Arg Leu Asp Ile Val Pro Leu Asp Asn
 65 70 75 80
 Asn Asn Asn Ser Thr Tyr Arg Leu Ile Asn Cys Asn Thr Ser Ala Ile
 85 90 95
 Thr Gln Ala Cys Pro Lys Val Thr Phe Asp Pro Ile Pro Ile His Tyr
 100 105 110
 Cys Ala Pro Ala Gly Tyr Ala Ile Leu Lys Cys Asn Asn Lys Thr Phe
 115 120 125
 Asn Gly Thr Gly Pro Cys His Asn Val Ser Thr Val Gln Cys Thr His
 130 135 140
 Gly Ile Ser Pro Val Val Ser Thr Gln Leu Leu Leu Asn Gly Ser Leu
 145 150 155 160
 Ala Glu Gly Glu Ile Ile Ile Arg Ser Glu Asn Leu Thr Asp Asn Val
 165 170 175
 Lys Thr Ile Ile Val His Leu Asn Gln Ser Val Glu Val Val Cys Thr
 180 185 190
 Arg Pro Asn Asn Asn Thr Arg Lys Ser Ile Arg Ile Gly Pro Gly Gln
 195 200 205
 Thr Phe Tyr Ala Thr Gly Asp Ile Ile Gly Asp Ile Arg Gln Ala His
 210 215 220
 Cys Asn Ile Ser Glu Asp Lys Trp Asn Glu Thr Leu Gln Arg Val Gly
 225 230 235 240
 Lys Lys Leu Ala Glu His Phe Pro Asn Lys Thr Ile Lys Phe Ala Ala
 245 250 255
 Ser Ser Gly Gly Asp Leu Glu Ile Thr Thr Tyr Ser Phe Asn Cys Arg
 260 265 270
 Gly Glu Phe Phe Tyr Cys Asn Thr Ser Gly Leu Phe Asn Gly Thr Tyr
 275 280 285
 Met Pro Asn Gly Thr Lys Ser Asn Leu Asn Ser Thr Ile Thr Ile Pro
 290 295 300
 Cys Arg Ile Lys Gln Ile Val Asn Leu Trp Gln Glu Val Gly Arg Ala
 305 310 315 320
 Met Tyr Ala Pro Pro Phe Ala Arg Asn Ile Thr Cys Lys Ser Asn Ile
 325 330 335
 Thr Gly Leu Leu Leu Val Arg Asp Gly Gly Glu Asp Thr Asn Asp Thr
 340 345 350
 Glu Ile Phe Ser Pro Gly Gly Gly Asp Met Arg Asp Asn Trp Arg Ser
 355 360 365
 Glu Leu Tyr Lys Tyr Lys Val Val Glu Ile Lys Pro Leu Gly Val Ala
 370 375 380
 Pro Thr Thr Ala Lys Arg Arg Val Val Glu Arg Glu Lys Arg Ala Val
 385 390 395 400
 Gly Leu Gly Ala Val Phe Leu Gly Phe Leu Gly Ala Ala Gly Ser Thr
 405 410 415
 Met Gly Ala Ala Ser Ile Thr Leu Thr Val Gln Ala Arg Gln Leu Leu
 420 425 430
 Ser Gly Ile Val Gln Gln Gln Ser Asn Leu Leu Arg Ala Ile Glu Ala
 435 440 445
 Gln Gln His Leu Leu Gln Leu Thr Val Trp Gly Ile Lys Gln Leu Gln
 450 455 460
 Thr Arg Val Leu Ala Ile Glu Arg Tyr Leu Lys Asp Gln Gln Leu Leu
 465 470 475 480
 Gly Met Trp Gly Cys Ser Gly Lys Leu Ile Cys Thr Thr Ala Val Pro
 485 490 495
 Trp Asn Ser Ser Trp Ser Asn Arg Ser Gln Thr Asp Ile Trp Asp Asn
 500 505 510
 Met Thr Trp Met Gln Trp Asp Arg Glu Ile Ser Asn Tyr Thr Asn Thr
 515 520 525
 Ile Tyr Arg Leu Leu Glu Asp Ser Gln Asn Gln Gln Glu Arg Asn Glu
 530 535 540
 Lys Asp Leu Leu Ala Leu Asp Ser Trp Lys Asn Leu Trp Asn Trp Phe
 545 550 555 560
 Ser Ile Thr Asn Trp Leu Trp Tyr Ile Lys Ile Phe Ile Met Ile Val
 565 570 575
 Gly Gly Leu Ile Gly Leu Arg Ile Ile Phe Ala Val Leu Ser Ile Val
 580 585 590
 Asn Arg Val Arg Gln Gly Tyr Ser Pro Leu Ser Phe Gln Thr
 595 600 605
 &lt;200&gt; SEQUENCE CHARACTERISTICS:
 &lt;210&gt; SEQ ID NO 7
 &lt;211&gt; LENGTH: 9
 &lt;212&gt; TYPE: PRT
 &lt;213&gt; ORGANISM: Human immunodeficiency virus
 &lt;400&gt; SEQUENCE: 7
 Met Pro Asn Gly Thr Lys Ser Asn Ser
 1 5
 &lt;200&gt; SEQUENCE CHARACTERISTICS:
 &lt;210&gt; SEQ ID NO 8
 &lt;211&gt; LENGTH: 9
 &lt;212&gt; TYPE: PRT
 &lt;213&gt; ORGANISM: Human immunodeficiency virus
 &lt;400&gt; SEQUENCE: 8
 Met Pro Asn Gly Thr Lys Gly Asn Ser
 1 5
 &lt;200&gt; SEQUENCE CHARACTERISTICS:
 &lt;210&gt; SEQ ID NO 9
 &lt;211&gt; LENGTH: 9
 &lt;212&gt; TYPE: PRT
 &lt;213&gt; ORGANISM: Human immunodeficiency virus
 &lt;400&gt; SEQUENCE: 9
 Met Pro Asn Gly Thr Lys Ser Asn Leu
 1 5
 &lt;200&gt; SEQUENCE CHARACTERISTICS:
 &lt;210&gt; SEQ ID NO 10
 &lt;211&gt; LENGTH: 14
 &lt;212&gt; TYPE: PRT
 &lt;213&gt; ORGANISM: Human immunodeficiency virus
 &lt;400&gt; SEQUENCE: 10
 Arg Asn Glu Lys Asp Leu Leu Ala Leu Asp Ser Trp Lys Asn
 1 5 10
 &lt;200&gt; SEQUENCE CHARACTERISTICS:
 &lt;210&gt; SEQ ID NO 11
 &lt;211&gt; LENGTH: 615
 &lt;212&gt; TYPE: PRT
 &lt;213&gt; ORGANISM: Human immunodeficiency virus
 &lt;220&gt; FEATURE:
 &lt;223&gt; OTHER INFORMATION: HIV-1(Bru)
 &lt;400&gt; SEQUENCE: 11
 Ser Leu Trp Asp Gln Ser Leu Lys Pro Cys Val Lys Leu Thr Pro Leu
 1 5 10 15
 Cys Val Ser Leu Lys Cys Thr Asp Leu Gly Asn Ala Thr Asn Thr Asn
 20 25 30
 Ser Ser Asn Thr Asn Ser Ser Ser Gly Glu Met Met Met Glu Lys Gly
 35 40 45
 Glu Ile Lys Asn Cys Ser Phe Asn Ile Ser Thr Ser Ile Arg Gly Lys
 50 55 60
 Val Gln Lys Glu Tyr Ala Phe Phe Tyr Lys Leu Asp Ile Ile Pro Ile
 65 70 75 80
 Asp Asn Asp Thr Thr Ser Tyr Thr Leu Thr Ser Cys Asn Thr Ser Val
 85 90 95
 Ile Thr Gln Ala Cys Pro Lys Val Ser Phe Glu Pro Ile Pro Ile His
 100 105 110
 Tyr Cys Ala Pro Ala Gly Phe Ala Ile Leu Lys Cys Asn Asn Lys Thr
 115 120 125
 Phe Asn Gly Thr Gly Pro Cys Thr Asn Val Ser Thr Val Gln Cys Thr
 130 135 140
 His Gly Ile Arg Pro Val Val Ser Thr Gln Leu Leu Leu Asn Gly Ser
 145 150 155 160
 Leu Ala Glu Glu Glu Val Val Ile Arg Ser Ala Asn Phe Thr Asp Asn
 165 170 175
 Ala Lys Thr Ile Ile Val Gln Leu Asn Gln Ser Val Glu Ile Asn Cys
 180 185 190
 Thr Arg Pro Asn Asn Asn Thr Arg Lys Ser Ile Arg Ile Gln Arg Gly
 195 200 205
 Pro Gly Arg Ala Phe Val Thr Ile Gly Lys Ile Gly Asn Met Arg Gln
 210 215 220
 Ala His Cys Asn Ile Ser Arg Ala Lys Trp Asn Ala Thr Leu Lys Gln
 225 230 235 240
 Ile Ala Ser Lys Leu Arg Glu Gln Phe Gly Asn Asn Lys Thr Ile Ile
 245 250 255
 Phe Lys Gln Ser Ser Gly Gly Asp Pro Glu Ile Val Thr His Ser Phe
 260 265 270
 Asn Cys Gly Gly Glu Phe Phe Tyr Cys Asn Ser Thr Gln Leu Phe Asn
 275 280 285
 Ser Thr Trp Phe Asn Ser Thr Trp Ser Thr Glu Gly Ser Asn Asn Thr
 290 295 300
 Glu Gly Ser Asp Thr Ile Thr Leu Pro Cys Arg Ile Lys Gln Phe Ile
 305 310 315 320
 Asn Met Trp Gln Glu Val Gly Lys Ala Met Tyr Ala Pro Pro Ile Ser
 325 330 335
 Gly Gln Ile Arg Cys Ser Ser Asn Ile Thr Gly Leu Leu Leu Thr Arg
 340 345 350
 Asp Gly Gly Asn Asn Asn Asn Gly Ser Glu Ile Phe Arg Pro Gly Gly
 355 360 365
 Gly Asp Met Arg Asp Asn Trp Arg Ser Glu Leu Tyr Lys Tyr Lys Val
 370 375 380
 Val Lys Ile Glu Pro Leu Gly Val Ala Pro Thr Lys Ala Lys Arg Arg
 385 390 395 400
 Val Val Gln Arg Glu Lys Arg Ala Val Gly Ile Gly Ala Leu Phe Leu
 405 410 415
 Gly Phe Leu Gly Ala Ala Gly Ser Thr Met Gly Ala Arg Ser Met Thr
 420 425 430
 Leu Thr Val Gln Ala Arg Gln Leu Leu Ser Gly Ile Val Gln Gln Gln
 435 440 445
 Asn Asn Leu Leu Arg Ala Ile Glu Ala Gln Gln His Leu Leu Gln Leu
 450 455 460
 Thr Val Trp Gly Ile Lys Gln Leu Gln Ala Arg Ile Leu Ala Val Glu
 465 470 475 480
 Arg Tyr Leu Lys Asp Gln Gln Leu Leu Gly Ile Trp Gly Cys Ser Gly
 485 490 495
 Lys Leu Ile Cys Thr Thr Ala Val Pro Trp Asn Ala Ser Trp Ser Asn
 500 505 510
 Lys Ser Leu Glu Gln Ile Trp Asn Asn Met Thr Trp Met Glu Trp Asp
 515 520 525
 Arg Glu Ile Asn Asn Tyr Thr Ser Leu Ile His Ser Leu Ile Glu Glu
 530 535 540
 Ser Gln Asn Gln Gln Glu Lys Asn Glu Gln Glu Leu Leu Glu Leu Asp
 545 550 555 560
 Lys Trp Ala Ser Leu Trp Asn Trp Phe Asn Ile Thr Asn Trp Leu Trp
 565 570 575
 Tyr Ile Lys Ile Phe Ile Met Ile Val Gly Gly Leu Val Gly Leu Arg
 580 585 590
 Ile Val Phe Ala Val Leu Ser Ile Val Asn Arg Val Arg Gln Gly Tyr
 595 600 605
 Ser Pro Leu Ser Phe Gln Thr
 610 615
 &lt;200&gt; SEQUENCE CHARACTERISTICS:
 &lt;210&gt; SEQ ID NO 12
 &lt;211&gt; LENGTH: 610
 &lt;212&gt; TYPE: PRT
 &lt;213&gt; ORGANISM: Human immunodeficiency virus
 &lt;220&gt; FEATURE:
 &lt;223&gt; OTHER INFORMATION: HIV-1(SF2)
 &lt;400&gt; SEQUENCE: 12
 Ser Leu Trp Asp Gln Ser Leu Lys Pro Cys Val Lys Leu Thr Pro Leu
 1 5 10 15
 Cys Val Thr Leu Asn Cys Thr Asp Leu Gly Lys Ala Thr Asn Thr Asn
 20 25 30
 Ser Ser Asn Trp Lys Glu Glu Ile Lys Gly Glu Ile Lys Asn Cys Ser
 35 40 45
 Phe Asn Ile Thr Thr Ser Ile Arg Asp Lys Ile Gln Lys Glu Asn Ala
 50 55 60
 Leu Phe Arg Asn Leu Asp Val Val Pro Ile Asp Asn Ala Ser Thr Thr
 65 70 75 80
 Thr Asn Tyr Thr Asn Tyr Arg Leu Ile His Cys Asn Arg Ser Val Ile
 85 90 95
 Thr Gln Ala Cys Pro Lys Val Ser Phe Glu Pro Ile Pro Ile His Tyr
 100 105 110
 Cys Thr Pro Ala Gly Phe Ala Ile Leu Lys Cys Asn Asn Lys Thr Phe
 115 120 125
 Asn Gly Lys Gly Pro Cys Thr Asn Val Ser Thr Val Gln Cys Thr His
 130 135 140
 Gly Ile Arg Pro Ile Val Ser Thr Gln Leu Leu Leu Asn Gly Ser Leu
 145 150 155 160
 Ala Glu Glu Glu Val Val Ile Arg Ser Asp Asn Phe Thr Asn Asn Ala
 165 170 175
 Lys Thr Ile Ile Val Gln Leu Asn Glu Ser Val Ala Ile Asn Cys Thr
 180 185 190
 Arg Pro Asn Asn Asn Thr Arg Lys Ser Ile Tyr Ile Gly Pro Gly Arg
 195 200 205
 Ala Phe His Thr Thr Gly Arg Ile Ile Gly Asp Ile Arg Lys Ala His
 210 215 220
 Cys Asn Ile Ser Arg Ala Gln Trp Asn Asn Thr Leu Glu Gln Ile Val
 225 230 235 240
 Lys Lys Leu Arg Glu Gln Phe Gly Asn Asn Lys Thr Ile Val Phe Asn
 245 250 255
 Gln Ser Ser Gly Gly Asp Pro Glu Ile Val Met His Ser Phe Asn Cys
 260 265 270
 Arg Gly Glu Phe Phe Tyr Cys Asn Thr Thr Gln Leu Phe Asn Asn Thr
 275 280 285
 Trp Arg Leu Asn His Thr Glu Gly Thr Lys Gly Asn Asp Thr Ile Ile
 290 295 300
 Leu Pro Cys Arg Ile Lys Gln Ile Ile Asn Met Trp Gln Glu Val Gly
 305 310 315 320
 Lys Ala Met Tyr Ala Pro Pro Ile Gly Gly Gln Ile Ser Cys Ser Ser
 325 330 335
 Asn Ile Thr Gly Leu Leu Leu Thr Arg Asp Gly Gly Thr Asn Val Thr
 340 345 350
 Asn Asp Thr Glu Val Phe Arg Pro Gly Gly Gly Asp Met Arg Asp Asn
 355 360 365
 Trp Arg Ser Glu Leu Tyr Lys Tyr Lys Val Ile Lys Ile Glu Pro Leu
 370 375 380
 Gly Ile Ala Pro Thr Lys Ala Lys Arg Arg Val Val Gln Arg Glu Lys
 385 390 395 400
 Arg Ala Val Gly Ile Val Gly Ala Met Phe Leu Gly Phe Leu Gly Ala
 405 410 415
 Ala Gly Ser Thr Met Gly Ala Val Ser Leu Thr Leu Thr Val Gln Ala
 420 425 430
 Arg Gln Leu Leu Ser Gly Ile Val Gln Gln Gln Asn Asn Leu Leu Arg
 435 440 445
 Ala Ile Glu Ala Gln Gln His Leu Leu Gln Leu Thr Val Trp Gly Ile
 450 455 460
 Lys Gln Leu Gln Ala Arg Val Leu Ala Val Glu Arg Tyr Leu Arg Asp
 465 470 475 480
 Gln Gln Leu Leu Gly Ile Trp Gly Cys Ser Gly Lys Leu Ile Cys Thr
 485 490 495
 Thr Ala Val Pro Trp Asn Ala Ser Trp Ser Asn Lys Ser Leu Glu Asp
 500 505 510
 Ile Trp Asp Asn Met Thr Trp Met Gln Trp Glu Arg Glu Ile Asp Asn
 515 520 525
 Tyr Thr Asn Thr Ile Tyr Thr Leu Leu Glu Glu Ser Gln Asn Gln Gln
 530 535 540
 Glu Lys Asn Glu Gln Glu Leu Leu Glu Leu Asp Lys Trp Ala Ser Leu
 545 550 555 560
 Trp Asn Trp Phe Ser Ile Thr Asn Trp Leu Trp Tyr Ile Lys Ile Phe
 565 570 575
 Ile Met Ile Val Gly Gly Leu Val Gly Leu Arg Ile Val Phe Ala Val
 580 585 590
 Leu Ser Ile Val Asn Arg Val Arg Gln Gly Tyr Ser Pro Leu Ser Phe
 595 600 605
 Gln Thr
 610
 &lt;200&gt; SEQUENCE CHARACTERISTICS:
 &lt;210&gt; SEQ ID NO 13
 &lt;211&gt; LENGTH: 608
 &lt;212&gt; TYPE: PRT
 &lt;213&gt; ORGANISM: Human immunodeficiency virus
 &lt;220&gt; FEATURE:
 &lt;223&gt; OTHER INFORMATION: HIV-1(Eli)
 &lt;400&gt; SEQUENCE: 13
 Ser Leu Trp Asp Gln Ser Leu Lys Pro Cys Val Lys Leu Thr Pro Leu
 1 5 10 15
 Cys Val Thr Leu Asn Cys Ser Asp Glu Leu Arg Asn Asn Gly Thr Met
 20 25 30
 Gly Asn Asn Val Thr Thr Glu Glu Lys Gly Met Lys Asn Cys Ser Phe
 35 40 45
 Asn Val Thr Thr Val Leu Lys Asp Lys Lys Gln Gln Val Tyr Ala Leu
 50 55 60
 Phe Tyr Arg Leu Asp Ile Val Pro Ile Asp Asn Asp Ser Ser Thr Asn
 65 70 75 80
 Ser Thr Asn Tyr Arg Leu Ile Asn Cys Asn Thr Ser Ala Ile Thr Gln
 85 90 95
 Ala Cys Pro Lys Val Ser Phe Glu Pro Ile Pro Ile His Tyr Cys Ala
 100 105 110
 Pro Ala Gly Phe Ala Ile Leu Lys Cys Arg Asp Lys Lys Phe Asn Gly
 115 120 125
 Thr Gly Pro Cys Thr Asn Val Ser Thr Val Gln Cys Thr His Gly Ile
 130 135 140
 Arg Pro Val Val Ser Thr Gln Leu Leu Leu Asn Gly Ser Leu Ala Glu
 145 150 155 160
 Glu Glu Val Ile Ile Arg Ser Glu Asn Leu Thr Asn Asn Ala Lys Asn
 165 170 175
 Ile Ile Ala His Leu Asn Glu Ser Val Lys Ile Thr Cys Ala Arg Pro
 180 185 190
 Tyr Gln Asn Thr Arg Gln Arg Thr Pro Ile Gly Leu Gly Gln Ser Leu
 195 200 205
 Tyr Thr Thr Arg Ser Arg Ser Ile Ile Gly Gln Ala His Cys Asn Ile
 210 215 220
 Ser Arg Ala Gln Trp Ser Lys Thr Leu Gln Gln Val Ala Arg Lys Leu
 225 230 235 240
 Gly Thr Leu Leu Asn Lys Thr Ile Ile Lys Phe Lys Pro Ser Ser Gly
 245 250 255
 Gly Asp Pro Glu Ile Thr Thr His Ser Phe Asn Cys Gly Gly Glu Phe
 260 265 270
 Phe Tyr Cys Asn Thr Ser Gly Leu Phe Asn Ser Thr Trp Asn Ile Ser
 275 280 285
 Ala Trp Asn Asn Ile Thr Glu Ser Asn Asn Ser Thr Asn Thr Asn Ile
 290 295 300
 Thr Leu Gln Cys Arg Ile Lys Gln Ile Ile Lys Met Val Ala Gly Arg
 305 310 315 320
 Lys Ala Ile Tyr Ala Pro Pro Ile Glu Arg Asn Ile Leu Cys Ser Ser
 325 330 335
 Asn Ile Thr Gly Leu Leu Leu Thr Arg Asp Gly Gly Ile Asn Asn Ser
 340 345 350
 Thr Asn Glu Thr Phe Arg Pro Gly Gly Gly Asp Met Arg Asp Asn Trp
 355 360 365
 Arg Ser Glu Leu Tyr Lys Tyr Lys Val Val Gln Ile Glu Pro Leu Gly
 370 375 380
 Val Ala Pro Thr Arg Ala Lys Arg Arg Val Val Glu Arg Glu Lys Arg
 385 390 395 400
 Ala Ile Gly Leu Gly Ala Met Phe Leu Gly Phe Leu Gly Ala Ala Gly
 405 410 415
 Ser Thr Met Gly Ala Arg Ser Val Thr Leu Thr Val Gln Ala Arg Gln
 420 425 430
 Leu Met Ser Gly Ile Val Gln Gln Gln Asn Asn Leu Leu Arg Ala Ile
 435 440 445
 Glu Ala Gln Gln His Leu Leu Gln Leu Thr Val Trp Gly Ile Lys Gln
 450 455 460
 Leu Gln Ala Arg Ile Leu Ala Val Glu Arg Tyr Leu Lys Asp Gln Gln
 465 470 475 480
 Leu Leu Gly Ile Trp Gly Cys Ser Gly Lys His Ile Cys Thr Thr Asn
 485 490 495
 Val Pro Trp Asn Ser Ser Trp Ser Asn Arg Ser Leu Asn Glu Ile Trp
 500 505 510
 Gln Asn Met Thr Trp Met Glu Trp Glu Arg Glu Ile Asp Asn Tyr Thr
 515 520 525
 Gly Leu Ile Tyr Ser Leu Ile Glu Glu Ser Gln Thr Gln Gln Glu Lys
 530 535 540
 Asn Glu Lys Glu Leu Leu Glu Leu Asp Lys Trp Ala Ser Leu Trp Asn
 545 550 555 560
 Trp Phe Ser Ile Thr Gln Trp Leu Trp Tyr Ile Lys Ile Phe Ile Met
 565 570 575
 Ile Ile Gly Gly Leu Ile Gly Leu Arg Ile Val Phe Ala Val Leu Ser
 580 585 590
 Leu Val Asn Arg Val Arg Gln Gly Tyr Ser Pro Leu Ser Phe Gln Thr
 595 600 605
 &lt;200&gt; SEQUENCE CHARACTERISTICS:
 &lt;210&gt; SEQ ID NO 14
 &lt;211&gt; LENGTH: 613
 &lt;212&gt; TYPE: PRT
 &lt;213&gt; ORGANISM: Human immunodeficiency virus
 &lt;220&gt; FEATURE:
 &lt;223&gt; OTHER INFORMATION: HIV-1(Mal)
 &lt;400&gt; SEQUENCE: 14
 Ser Leu Trp Asp Gln Ser Leu Lys Pro Cys Val Lys Leu Thr Pro Leu
 1 5 10 15
 Cys Val Thr Leu Asn Cys Thr Asn Val Asn Gly Thr Ala Val Asn Gly
 20 25 30
 Thr Asn Ala Gly Ser Asn Arg Thr Asn Ala Glu Leu Lys Met Glu Ile
 35 40 45
 Gly Glu Val Lys Asn Cys Ser Phe Asn Ile Thr Pro Val Gly Ser Asp
 50 55 60
 Lys Arg Gln Glu Tyr Ala Thr Phe Tyr Asn Leu Asp Leu Val Gln Ile
 65 70 75 80
 Asp Asp Ser Asp Asn Ser Ser Tyr Arg Leu Ile Asn Cys Asn Thr Ser
 85 90 95
 Val Ile Thr Gln Ala Cys Pro Lys Val Thr Phe Asp Pro Ile Pro Ile
 100 105 110
 His Tyr Cys Ala Pro Ala Gly Phe Ala Ile Leu Lys Cys Asn Asp Lys
 115 120 125
 Lys Phe Asn Gly Thr Glu Ile Cys Lys Asn Val Ser Thr Val Gln Cys
 130 135 140
 Thr His Gly Ile Lys Pro Val Val Ser Thr Gln Leu Leu Leu Asn Gly
 145 150 155 160
 Ser Leu Ala Glu Glu Glu Ile Met Ile Arg Ser Glu Asn Leu Thr Asp
 165 170 175
 Asn Thr Lys Asn Ile Ile Val Gln Leu Asn Glu Thr Val Thr Ile Asn
 180 185 190
 Cys Thr Arg Pro Gly Asn Asn Thr Arg Arg Gly Ile His Phe Gly Pro
 195 200 205
 Gly Gln Ala Leu Tyr Thr Thr Gly Ile Val Gly Asp Ile Arg Arg Ala
 210 215 220
 Tyr Cys Thr Ile Asn Glu Thr Glu Trp Asp Lys Thr Leu Gln Gln Val
 225 230 235 240
 Ala Val Lys Leu Gly Ser Leu Leu Asn Lys Thr Lys Ile Ile Phe Asn
 245 250 255
 Ser Ser Ser Gly Gly Asp Pro Glu Ile Thr Thr His Ser Phe Asn Cys
 260 265 270
 Arg Gly Glu Phe Phe Tyr Cys Asn Thr Ser Lys Leu Phe Asn Ser Thr
 275 280 285
 Trp Gln Asn Asn Gly Ala Arg Leu Ser Asn Ser Thr Glu Ser Thr Gly
 290 295 300
 Ser Ile Thr Leu Pro Cys Arg Ile Lys Gln Ile Ile Asn Met Trp Gln
 305 310 315 320
 Lys Thr Gly Lys Ala Met Tyr Ala Pro Pro Ile Ala Gly Val Ile Asn
 325 330 335
 Cys Leu Ser Asn Ile Thr Gly Leu Ile Leu Thr Arg Asp Gly Gly Asn
 340 345 350
 Ser Ser Asp Asn Ser Asp Asn Glu Thr Leu Arg Pro Gly Gly Gly Asp
 355 360 365
 Met Arg Asp Asn Trp Ile Ser Glu Leu Tyr Lys Tyr Lys Val Val Arg
 370 375 380
 Ile Glu Pro Leu Gly Val Ala Pro Thr Lys Ala Lys Arg Arg Val Val
 385 390 395 400
 Glu Arg Glu Lys Arg Ala Ile Gly Leu Gly Ala Met Phe Leu Gly Phe
 405 410 415
 Leu Gly Ala Ala Gly Ser Thr Met Gly Ala Ala Ser Leu Thr Leu Thr
 420 425 430
 Val Gln Ala Arg Gln Leu Leu Ser Gly Ile Val Gln Gln Gln Asn Asn
 435 440 445
 Leu Leu Arg Ala Ile Glu Ala Gln Gln His Leu Leu Gln Leu Thr Val
 450 455 460
 Trp Gly Ile Lys Gln Leu Gln Ala Arg Val Leu Ala Val Glu Arg Tyr
 465 470 475 480
 Leu Gln Asp Gln Arg Leu Leu Gly Met Trp Gly Cys Ser Gly Lys His
 485 490 495
 Ile Cys Thr Thr Phe Val Pro Trp Asn Ser Ser Trp Ser Asn Arg Ser
 500 505 510
 Leu Asp Asp Ile Trp Asn Asn Met Thr Trp Met Gln Trp Glu Lys Glu
 515 520 525
 Ile Ser Asn Tyr Thr Gly Ile Ile Tyr Asn Leu Ile Glu Glu Ser Gln
 530 535 540
 Ile Gln Gln Glu Lys Asn Glu Lys Glu Leu Leu Glu Leu Asp Lys Trp
 545 550 555 560
 Ala Ser Leu Trp Asn Trp Phe Ser Ile Ser Lys Trp Leu Trp Tyr Ile
 565 570 575
 Arg Ile Phe Ile Ile Val Val Gly Gly Leu Ile Gly Leu Arg Ile Ile
 580 585 590
 Phe Ala Val Leu Ser Leu Val Asn Arg Val Arg Gln Gly Tyr Ser Pro
 595 600 605
 Leu Ser Leu Gln Thr
 610
 &lt;200&gt; SEQUENCE CHARACTERISTICS:
 &lt;210&gt; SEQ ID NO 15
 &lt;211&gt; LENGTH: 602
 &lt;212&gt; TYPE: PRT
 &lt;213&gt; ORGANISM: Simian immunodeficiency virus
 &lt;220&gt; FEATURE:
 &lt;223&gt; OTHER INFORMATION: SIVcpz
 &lt;400&gt; SEQUENCE: 15
 Ser Leu Trp Asp Gln Ser Leu Lys Pro Cys Val Lys Leu Thr Pro Leu
 1 5 10 15
 Cys Val Thr Leu Gln Cys Ser Lys Ala Asn Phe Ser Gln Ala Lys Asn
 20 25 30
 Leu Thr Asn Gln Thr Ser Ser Pro Pro Leu Glu Met Lys Asn Cys Ser
 35 40 45
 Phe Asn Val Thr Thr Glu Leu Arg Asp Lys Lys Lys Gln Val Tyr Ser
 50 55 60
 Leu Phe Tyr Val Glu Asp Val Val Asn Leu Gly Asn Glu Asn Asn Thr
 65 70 75 80
 Tyr Arg Ile Ile Asn Cys Asn Thr Thr Ala Ile Thr Gln Ala Cys Pro
 85 90 95
 Lys Thr Ser Phe Glu Pro Ile Pro Ile His Tyr Cys Ala Pro Ala Gly
 100 105 110
 Phe Ala Ile Leu Lys Cys Asn Asp Lys Asp Phe Ser Gly Lys Gly Lys
 115 120 125
 Cys Thr Asn Val Ser Thr Val His Cys Thr His Gly Ile Lys Pro Val
 130 135 140
 Val Thr Thr Gln Leu Leu Ile Asn Gly Ser Leu Ala Glu Gly Asn Ile
 145 150 155 160
 Thr Val Arg Val Glu Asn Lys Ser Lys Asn Thr Asp Val Trp Ile Val
 165 170 175
 Gln Leu Val Glu Ala Val Ser Leu Asn Cys His Arg Pro Gly Asn Asn
 180 185 190
 Thr Arg Gly Glu Val Gln Ile Gly Pro Gly Met Thr Phe Tyr Asn Ile
 195 200 205
 Glu Asn Val Val Gly Asp Thr Arg Ser Ala Tyr Cys Lys Ile Asn Gly
 210 215 220
 Thr Thr Trp Asn Arg Thr Val Glu Glu Val Lys Lys Ala Leu Ala Thr
 225 230 235 240
 Ser Ser Asn Arg Thr Ala Ala Asn Ile Thr Leu Asn Arg Ala Ser Gly
 245 250 255
 Gly Asp Pro Glu Val Thr His His Met Phe Asn Cys Gly Gly Glu Phe
 260 265 270
 Phe Tyr Cys Asn Thr Ser Gln Ile Phe Thr Asp Asn Ile Thr Asn Gly
 275 280 285
 Ile Ile Ile Leu Pro Cys Arg Ile Arg Gln Ile Val Ser Ser Trp Met
 290 295 300
 Arg Val Gly Arg Gly Ile Tyr Ala Pro Pro Ile Arg Gly Asn Ile Thr
 305 310 315 320
 Cys Asn Ser Asn Ile Thr Gly Leu Leu Leu Thr Ser Asp Thr Pro Val
 325 330 335
 Thr Asn Asn Ser Gly Asn Leu Thr Phe Arg Pro Thr Gly Gly Asn Met
 340 345 350
 Lys Asp Ile Trp Arg Ser Glu Leu Tyr Lys Tyr Lys Val Val Arg Ile
 355 360 365
 Glu Pro Leu Ser Val Ala Pro Thr Lys Ala Arg Arg His Thr Val Ala
 370 375 380
 Arg Gln Lys Asp Arg Gln Lys Arg Ala Ala Phe Gly Leu Gly Ala Leu
 385 390 395 400
 Phe Leu Gly Phe Leu Gly Ala Ala Gly Ser Thr Met Gly Ala Ala Ala
 405 410 415
 Val Thr Leu Thr Val Gln Ala Arg Gln Leu Leu Ser Gly Ile Val Gln
 420 425 430
 Gln Gln Asn Asn Leu Leu Lys Ala Ile Glu Ala Gln Gln His Leu Leu
 435 440 445
 Gln Leu Ser Ile Trp Gly Val Lys Gln Leu Gln Ala Arg Leu Leu Ala
 450 455 460
 Val Glu Arg Tyr Leu Gln Asp Gln Gln Ile Leu Gly Leu Trp Gly Cys
 465 470 475 480
 Ser Gly Lys Ala Val Cys Tyr Thr Thr Val Pro Trp Asn Asn Ser Trp
 485 490 495
 Pro Gly Ser Asn Ser Thr Asp Asp Ile Trp Gly Asn Leu Thr Trp Gln
 500 505 510
 Gln Trp Asp Lys Leu Val Ser Asn Tyr Thr Gly Lys Ile Phe Gly Leu
 515 520 525
 Leu Glu Glu Ala Gln Ser Gln Gln Glu Lys Asn Glu Arg Asp Leu Leu
 530 535 540
 Glu Leu Asp Gln Trp Ala Ser Leu Trp Asn Trp Phe Asp Ile Thr Lys
 545 550 555 560
 Trp Leu Trp Tyr Ile Lys Ile Phe Leu Met Ala Val Gly Gly Ile Ile
 565 570 575
 Gly Leu Arg Ile Ile Met Thr Val Phe Ser Val Val Arg Arg Val Arg
 580 585 590
 Gln Gly Tyr Ser Pro Leu Ser Leu Gln Thr
 595 600